DARA BioSciences, Inc. (DARA)

[macjockey]

I could see Dara in the 1.50-2.50 range somewhere with some partnership news. Some additional factors would be how earnings look early next month. Remember that they will be able to pull that waiver money into that fourth quarter because the FDA expenses were accrued in 2013 and 2014. So its likely that earnings could be a near break even, with partnership news further locking in longevity. I actually expect FDA and partnership news in the next 2-6 weeks. In their investors slide deck, they site FDA and partnership news in early 2015.

Jason Napodano has called Dara an "enigma" for its trading patterns. Most other stocks in this stage would be in the 1.20-1.40 zone, and when announcing a 1.1 million dollar credit on FDA waivers with the stock at 1.07 pre-market, it drops 8% which is just ridiculous. Until there is news, we are probably stuck here.